Search

You searched for "POAG"

52 results found

Moorfields Education: Glaucoma level 3 (College of Optometrists Professional Diploma in Glaucoma) 2025

13 January 2025 -1 July 2025
This course is designed to build up from levels 1 and 2 to further develop skills in detecting change in clinical status and decision-making in patients with established glaucoma of all types in adult patients. Entry requirementsPossess a minimum of...

How much money is wasted on tests prior to cataract surgery? And why?

1 June 2015 | | EYE - Cataract, EYE - Refractive
For routine cataract surgery, numerous studies have found that preoperative testing does not contribute usefully to safety or surgical success. Despite such guidelines, tests ordered for patients prior to phacoemulsification in the US remains high. To quantify the associated costs,...

Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative follow up

29 March 2023 | glaucoma
Chavanod (near Annecy), France, March 29, 2023 - Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, announced the positive results of a 24-month post-operative follow-up on a clinical trial of CID, its first generation Cilio-scleral Inter-positioning Device.

Braille phones, glaucoma implants and screenshots

1 December 2014 | | EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Neuro-ophthalmology, EYE - Imaging, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
Basic phone for Braille readers (or kids and the elderly) We’ve previously covered the extensive features of smartphones that can help the sight impaired. It’s clear, however, that smartphones are not for everyone. One alternative is a custom made Braille...

Cutting-edge practice in glaucoma care: what, how and why?

1 April 2016 | | EYE - Glaucoma
More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...

“Beware of the pigment”

4 August 2021 | | EYE - Glaucoma, EYE - General
Using some captivating artwork, Iheukwumere Duru describes key features of pigment dispersion syndrome. Pigmentary dispersion syndrome (PDS) leads to pigmentary glaucoma (PG) in approximately 35-50% of patients with the condition [1]. PG is the leading cause of non-traumatic blindness in...

Patient and public participation shapes biomedical research and access priorities in eye health

1 December 2014 | | EYE - General
Patients, clinicians and clinician-scientists play a valuable role in shaping the future of vision research. Limited funding demands targeted research initiatives that ultimately will shape health policy and practice to secure progress in improving patient outcomes in eye health. This...

A closer look at the new wave of glaucoma surgery – radical or old school?

1 October 2016 | | EYE - Glaucoma
Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...

RCOphth Annual Congress - Day 3

25 May 2022 |
Follow live updates and key highlights from Day 3 of the RCOphth Annual Congress.

Contemporary glaucoma therapy: spoilt for choice

1 April 2014 | | EYE - Glaucoma
The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

Glaucoma-NET: a novel way of improving glaucoma management in sub-Saharan Africa

1 June 2022 | | EYE - Cornea, EYE - General
Background Glaucoma is the second most common cause of blindness worldwide [1]. People with untreated glaucoma suffer from irreversible, progressive loss of sight. The disease is characterised by progressive loss of visual field, with pathological cupping of the optic disc...

Sight Sciences Celebrates 150th Certified UK OMNI Surgeon

13 June 2025 | Awards, Conferences & Anniversaries, Company Profiles, Research & Development
Sight Sciences is proud to announce that 150 ophthalmic surgeons in the United Kingdom are now certified to use the OMNI® Surgical System. This milestone was marked by the recent certification of Ms. Diana Urbaneja, Consultant Ophthalmic Surgeon at University...